MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss available
to common shares
-$2,198,991
Net loss
-$2,198,991
Loss from operations
-$2,197,654
Total other expense,
net
-$1,337
Total operating
expenses
$2,197,654
Interest expense
$1,337
Research and development
$1,278,629
General and
administrative
$919,025
Back
Back
Income Statement
source: myfinsight.com
Alzamend Neuro, Inc. (ALZN)
Alzamend Neuro, Inc. (ALZN)